Show simple item record

dc.contributor.authorSeffer, Malin-Theres
dc.contributor.authorCottam, Daniel
dc.contributor.authorForni, Lui G
dc.contributor.authorKielstein, Jan T
dc.date.accessioned2020-08-05T13:18:21Z
dc.date.available2020-08-05T13:18:21Z
dc.date.issued2020-07-02
dc.identifier.citationBlood Purif. 2020;1-7. doi:10.1159/000508647.en_US
dc.identifier.pmid32615569
dc.identifier.doi10.1159/000508647
dc.identifier.urihttp://hdl.handle.net/10033/622387
dc.description.abstractIn April 2020, the US Food and Drug Administration granted emergency use authorization for certain medical devices to be used in patients with coronavirus disease 2019 (CO-VID-19). This included extracorporeal blood purification devices. This narrative review will give a brief overview regarding some of the extracorporeal devices that could be used to treat COVID-19 patients, including the Seraph® 100 Microbind® Affinity Blood Filter, produced by ExThera Medical (Martinez, CA, USA), first licensed in the European Economic Area in 2019. The Seraph® 100 contains ultrahigh molecular weight polyethylene beads with end point-attached heparin and is approved for the reduction of pathogens from the bloodstream either as a single agent or as an adjunct to conventional anti-infective agents. Bacteria, viruses, fungi, and toxins have been shown to bind to the immobilized heparin in a similar way to the interaction with heparan sulfate on the cell surface. This binding is nonreversible and as such, the pathogens are removed from the bloodstream. In this review, we describe the pathophysiological basis and rationale for using heparin for pathogen removal from the blood as well as exploring the technology behind the adaptation of heparin to deprive it of its systemic anticoagulant activity. In addition, we summarize the in vitro data as well as the available preclinical testing and published clinical reports. Finally, we discuss the enormous potential of this technology in an era of increasing antibiotic resistance and high mortality associated with sepsis and consider the application of this as a possible treatment option for COVID-19.en_US
dc.language.isoenen_US
dc.publisherKarger AGen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectAntibiotic resistanceen_US
dc.subjectBlood purificationen_US
dc.subjectExtracorporeal therapyen_US
dc.titleHeparin 2.0: A New Approach to the Infection Crisis.en_US
dc.typeReviewen_US
dc.typeOtheren_US
dc.identifier.eissn1421-9735
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalBlood purificationen_US
dc.source.beginpage1
dc.source.endpage7
refterms.dateFOA2020-08-05T13:18:22Z
dc.source.journaltitleBlood purification
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Seffer et al.pdf
Size:
605.1Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International